Els Van Valckenborgh
Overview
Explore the profile of Els Van Valckenborgh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
De Beule N, de Veirman K, Maes K, de Bruyne E, Menu E, Breckpot K, et al.
J Pathol
. 2016 Dec;
241(4):534-546.
PMID: 27976373
Overcoming drug resistance is one of the greatest challenges in the treatment of multiple myeloma (MM). The interaction of myeloma cells with the bone marrow (BM) microenvironment is a major...
12.
Johnsen H, Bogsted M, Schmitz A, Bodker J, El-Galaly T, Johansen P, et al.
Haematologica
. 2016 Dec;
101(12):1451-1459.
PMID: 27903712
The concept of the myeloma stem cell may have important therapeutic implications, yet its demonstration has been hampered by a lack of consistency in terms and definitions. Here, we summarize...
13.
Binsfeld M, Muller J, Lamour V, de Veirman K, De Raeve H, Bellahcene A, et al.
Oncotarget
. 2016 May;
7(25):37931-37943.
PMID: 27177328
Multiple myeloma (MM) is a plasma cell malignancy characterized by the accumulation of tumor cells in the bone marrow (BM) and is associated with immunosuppression, angiogenesis and osteolysis. Myeloid-derived suppressor...
14.
Bieghs L, Johnsen H, Maes K, Menu E, Van Valckenborgh E, Overgaard M, et al.
Oncotarget
. 2016 Apr;
7(30):48732-48752.
PMID: 27129151
Multiple myeloma (MM) is a highly heterogeneous plasma cell malignancy. The MM cells reside in the bone marrow (BM), where reciprocal interactions with the BM niche foster MM cell survival,...
15.
de Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, et al.
Cancer Lett
. 2016 Apr;
377(1):17-24.
PMID: 27102001
Mutual communication between multiple myeloma (MM) cells and mesenchymal stromal cells (MSC) plays a pivotal role in supporting MM progression. In MM, MSC exhibit a different genomic profile and dysregulated...
16.
Dufait I, Van Valckenborgh E, Menu E, Escors D, De Ridder M, Breckpot K
Oncotarget
. 2016 Mar;
7(27):42698-42715.
PMID: 27029037
Cancer progression is in part determined by interactions between cancer cells and stromal cells in the tumor microenvironment (TME). The identification of cytotoxic tumor-infiltrating lymphocytes has instigated research into immune...
17.
Wang J, Faict S, Maes K, de Bruyne E, Van Valckenborgh E, Schots R, et al.
Oncotarget
. 2016 Mar;
7(25):38927-38945.
PMID: 26950273
The bone marrow (BM) represents a complex microenvironment containing stromal cells, immune cells, osteoclasts, osteoblasts, and hematopoietic cells, which are crucial for the immune response, bone formation, and hematopoiesis. Apart...
18.
Lub S, Maes A, Maes K, de Veirman K, de Bruyne E, Menu E, et al.
Oncotarget
. 2015 Dec;
7(4):4062-76.
PMID: 26716651
The anaphase promoting complex/cyclosome (APC/C) is an ubiquitin ligase involved in cell cycle. During the metaphase-anaphase transition the APC/C is activated by Cdc20. The aim of this study is to...
19.
Lub S, Maes K, Menu E, de Bruyne E, Vanderkerken K, Van Valckenborgh E
Oncotarget
. 2015 Dec;
7(6):6521-37.
PMID: 26695547
Multiple myeloma (MM) is a hematological malignancy characterized by the accumulation of plasma cells in the bone marrow (BM). The success of the proteasome inhibitor bortezomib in the treatment of...
20.
Lawson M, McDonald M, Kovacic N, Khoo W, Terry R, Down J, et al.
Nat Commun
. 2015 Dec;
6:8983.
PMID: 26632274
Multiple myeloma is largely incurable, despite development of therapies that target myeloma cell-intrinsic pathways. Disease relapse is thought to originate from dormant myeloma cells, localized in specialized niches, which resist...